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ABSTRACT
Objectives: Serum uric acid has been suggested to be associated with cancer risk. 
We aimed to study the association between serum uric acid and cancer incidence in 
a large Swedish cohort.
Results: A positive association was found between uric acid levels and overall 
cancer risk, and results were similar with adjustment for glucose, triglycerides and 
BMI. Hazard ratio (HR) for overall cancer for the 4th quartile of uric acid compared 
to the 1st was 1.08 (95% CI: 1.05–1.11) in men and 1.12 (1.09 – 1.16) in women. 
Site-specific analysis showed a positive association between uric acid and risk of 
colorectal, hepatobiliary, kidney, non-melanoma skin, and other cancers in men and 
of head and neck and other cancers in women. An inverse association was observed 
for pulmonary and central nervous system (CNS) cancers in men and breast, lymphatic 
and haematological, and CNS malignancies in women.
Materials and Methods: We included 493,281 persons aged 20 years and older 
who had a measurement of serum uric acid and were cancer-free at baseline in 
the AMORIS study. Multivariable Cox proportional hazards regression was used to 
investigate sex-specific quartiles of serum uric acid in relation to cancer risk in men 
and women. Analysis was further adjusted for serum glucose, triglycerides and, where 
available, BMI. Site-specific analysis was performed for major cancers.
Conclusions: Altered uric acid levels were associated with risk of overall and 
some specific cancers, further indicating the potential role of uric acid metabolism 
in carcinogenesis.
INTRODUCTION
Uric acid is the product of the metabolism of dietary 
or endogenous adenine-based and guanine-based purines, 
and is excreted by the kidney and gut [1, 2]. Uric acid 
has paradoxically been found to have the characteristic 
of being an antioxidant in the extracellular environment, 
whilst having prooxidative effects in the intracellular 
environment [3, 4]. As an antioxidant, uric acid acts as 
a scavenger of oxygen radicals, and thus may serve to 
reduce carcinogenic reactive oxygen species (ROS) [2, 
5]. ROS are carcinogenic as they increase the mutation 
rate in cells, and therefore increase their oncogenic 
potential [5, 6]. As a prooxidant, uric acid contributes to 
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tumourigenesis by entering normal cells and promoting 
tumour cell proliferation, migration, and survival, 
mediated by ROS and inflammatory stress [7]. Recent 
epidemiological studies looking at the association of serum 
uric acid and cancer incidence have found conflicting 
results. A cohort study of 354,110 participants in Taiwan 
supported the hypothesis that uric acid was cancer-
protective as it suggested that low serum uric acid levels 
were associated with a higher risk of all cancer mortality 
relative to high serum uric acid levels [8]. Conversely, a 
cohort study of 83,683 participants in Austria found that 
high levels of serum uric acid were linked to a higher risk 
of all cancer mortality [9]. Furthermore, a cohort study of 
8,274 participants in China found that incidence of cancer 
increased with serum uric acid levels, but only in females 
with diabetes [10]. A recent systematic review and meta-
analysis of 17 studies on the link between serum uric acid 
and cancer incidence and mortality was inconclusive [2].
A link between uric acid and cancer that involves 
metabolic syndrome (MetS) has also been speculated. 
MetS is characterised by insulin resistance, hypertension, 
abnormal lipids, and chronic inflammation [11]. MetS is 
associated with higher frequencies of elevated serum uric 
acid levels (hyperuricemia), and, likewise, hyperuricemia 
is associated with subsequent MetS [12, 13]. Furthermore, 
studies using genetic uric acid scores as instrumental 
variables suggested uric acid has a bystander role in MetS 
[14]. Despite this strong relationship, the effect of MetS 
on the association between uric acid and cancer has not 
yet been explored.
High consumption of animal protein and seafood have 
been associated with higher prevalence of hyperuricemia 
[15]. Such consumption habits may reflect an unhealthy 
diet and lifestyle [16], suggesting serum uric acid is an 
inverse marker of health. Several studies have shown 
that high serum uric acid is an independent risk factor for 
hypertension [17], diabetes [18], CVD, and mortality [19].
We studied the association between serum uric acid 
levels and the incidence of overall and site-specific cancer 
in the Swedish Apolipoprotein-related MOrtality RISk 
study (AMORIS) including 493,281 adults, who were 
followed-up for up to 25 years. Additionally, we took into 
account serum glucose and triglycerides levels to account 
for the potential confounding by MetS on the association 
between circulating uric acid and cancer risk.
RESULTS
A total of 72,349 persons developed cancer during 
follow up (mean: 19.47 years). More cancers were 
observed in men (56.96%). The mean age of participants 
at baseline was 45 years. The majority of the study 
population (90.7%) was gainfully employed (Table 1). 
Overall, participants with cancer diagnosis during follow-
up had higher baseline uric acid levels compared to the 
group without cancer.
Higher cancer risk was observed with increasing 
levels of serum uric acid (Table 2), with a HR of 1.09 
(95%CI: 1.06 – 1.13) for each log unit increase of serum 
uric acid in the multivariable model. Results were similar 
with the crude levels of uric acid (data not shown). Further 
adjustment for serum glucose and TG showed similar 
results (e.g. HR for overall cancer for each log unit increase 
of serum uric acid was 1.07 (95%CI: 1.03 – 1.11)). Analysis 
in the subgroup with information of BMI showed similar 
albeit weaker results owing to smaller sample size, for 
instance, HR for every log unit increase of serum uric acid 
was 1.11 (95%CI: 1.00 – 1.24)) whereas the trend for the 
quartiles of serum uric acid was weaker (Ptrend = 0.07). No 
marked difference was seen with adjustment for BMI. 
A sensitivity analysis excluding participants with follow 
up less than 2 years was consistent with these results 
(Supplementary Table 2, Supplementary Information). A 
positive association was also found between uric acid levels 
and risk of death (Supplementary Table 3, Supplementary 
Information). When analysis was stratified by gender, 
similar associations were observed in men (e.g. HR for 
log unit increase of serum uric acid: 1.18 (95%CI: 1.12 – 
1.24)) and women (e.g. HR for log unit increase of serum 
uric acid: 1.23 (95%CI: 1.17 – 1.29)), although we found a 
statistically significant interaction between serum uric acid 
level and gender (Table 3).
Tables 4 and 5 show the association between 
serum uric acid levels and different site-specific cancers 
in men and women, respectively. In men, statistically 
significant positive associations were found for colorectal, 
hepatobillary, kidney, and non-melanoma skin cancers, and 
statistically significant inverse associations were found 
for pulmonary cancers. In women, statistically significant 
positive associations were found for head and neck 
cancers, and statistically significant inverse associations 
were found for breast, and lymphatic and haematological 
cancers in women. The hazard ratios (HRs) for positive 
associations were the largest for hepatobillary cancers 
in men (e.g. HR for log unit increase of serum uric acid: 
2.03 (95%CI: 1.38 – 2.99)) (Table 4) and for head and 
neck cancers in women (e.g. HR for log unit increase of 
serum uric acid: 1.90 (95%CI: 1.24 – 2.92)) (Table 5). The 
inverse HRs were the largest for CNS cancers in both men 
and women (e.g. HR for log unit increase of serum uric 
acid: 0.60 (95%CI: 0.43 – 0.83) and 0.67 (95%CI: 0.50 – 
0.89), respectively).
After Bonferroni correction for multiple testing, we 
found that the associations in colorectal, hepatobillary, 
and non-melanoma skin cancers remained significant in 
men, and associations in CNS and other cancers remained 
significant in women.
DISCUSSION
We observed that elevated levels of serum uric acid 
were associated with an increased cancer incidence in 
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comparison to normal values. Adjustment for glucose and 
TG did not alter the results, and trends were similar when 
adjusted for BMI. Cancer site specific and gender stratified 
analysis showed that positive associations between serum 
uric acid levels and risk of colorectal, hepatobillary, 
kidney, and non-melanoma skin cancers in men. For 
women this was observed for head and neck cancers.
Uric acid has been found to act as both an antioxidant 
and a prooxidant, both of which may affect carcinogenesis. 
Uric acid behaves as an antioxidant as it scavenges free 
radical and chelating transitional metal ions by preventing 
peroxynitrite-induced protein nitrosylation, lipid and protein 
peroxidation and inactivating tetrahydrobiopterin [20]. 
Experiments in which uric acid was administered to healthy 
volunteers found it to decrease ROS production [21]. 
Conversely, cells exposed to uric acid generate oxidative 
stress [22, 23]. Production of ROS is associated with local 
inflammation, impaired nitric oxide (NO) generation, 
activation of the renin-angiotensin-aldosterone system, 
insulin resistance, and fat accumulation [20], and promotes 
tumour cell proliferation, migration, and survival [7]. 
Tumourigenesis may occur because ROS increase cellular 
mutation rate, giving rise to oncogenic potential [5, 6].
We observed that elevated levels of serum uric acid 
were associated with increased incidence at some cancer 
sites and decreased incidence at other cancer sites, in 
Table 1: Descriptive characteristics of study population by cancer status
No Cancer
N=420,932
Cancer
N=72,349
Age (years)
 Mean (SD) 43.22 (13.75) 52.56 (11.51)
Gender – N (%)
 Male 223592 (53.12) 41207 (56.96)
 Female 197340 (46.88) 31142 (43.04)
Education Level – N (%)
 Low 102391 (25.43) 22088 (32.02)
 Medium 182446 (45.31) 28896 (41.90)
 High 117833 (29.26) 17988 (26.08)
Socioeconomic Status – N (%)
 White collar 194672 (46.25) 37281 (51.53)
 Blue collar 185694 (44.11) 29787 (41.17)
 Not gainfully employed/missing 40566 (9.64) 5281 (7.30)
Serum Uric Acid* – N (%)
 Quartile 1 105080 (24.96) 15770 (21.80)
 Quartile 2 107181 (25.46) 17114 (23.65)
 Quartile 3 105913 (25.16) 18528 (25.61)
 Quartile 4 102758 (24.41) 20937 (28.94)
Follow up time (years)
 Mean (SD) 20.51 (5.35) 13.43 (6.68)
CCI category – N (%)
 0 399736 (94.96) 67444 (93.22)
 1 15218 (3.62) 3597 (4.97)
 2 3666 (0.87) 795 (1.10)
 3+ 2312 (0.55) 513 (0.71)
*Serum uric acid quartiles (μmol/L): Quartile 1 (<281), quartile 2 (281-319), quartile 3 (319-362), quartile 4 (>362) in men, 
quartile 1 (<207), quartile 2 (207-240), quartile 3 (240-279), quartile 4 (>279) in women. CCI = Charlson comorbidity. index.
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comparison to normal values, supporting a paradoxical 
role for uric acid. Cancer site specific and gender stratified 
analysis showed positive associations between serum uric 
acid level and risk of colorectal, hepatobillary, kidney, and 
non-melanoma skin cancers in men, and head and neck 
cancers in women. Inverse associations between serum 
uric acid level and risk of pulmonary cancers in men, 
and breast, and lymphatic and haematological cancers in 
women were also shown.
In the current study, the positive associations 
between serum uric acid levels and cancer incidence 
support the role of uric acid as a prooxidant for the 
relevant cancer sites. Hyperuricemia is, therefore, a 
potential risk factor for colorectal, hepatobillary, kidney, 
non-melanoma skin, and other cancers in men, and for 
head and neck and other cancers in women. Conversely, 
hyperuricemia may be protective for pulmonary and 
CNS cancers in men, and for breast, lymphatic and 
haematological, and CNS cancers in women. The 
differing directions of association may imply variation 
in cellular responses to oxidative stress, or in the extent 
of involvement of oxidative stress and antioxidants 
in specific cancer development. Variation in cellular 
responses has previously been observed in other cellular 
stressors, for example, heterogeneous responses to 
anoxia in neurones [24].
Table 2: Hazard ratios (HR) and 95% Confidence Intervals (95%CI) for the risk of cancer by log and sex-specific 
quartiles of serum uric acid
HR (95%CI)
Model 1 Model 2* Model 3† Model 4§
N (Cancer/Total 
Participants)
72,349/493,281 72,349/493,281 72,349/493,281 9,447/66,931
Log serum uric acid 1.94 (1.88 – 2.00) 1.09 (1.06 – 1.13) 1.07 (1.03 – 1.11) 1.11 (1.00 – 1.24)
Serum uric acid
 Quartile 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
 Quartile 2 1.05 (1.03 – 1.07) 1.00 (0.98 – 1.03) 1.00 (0.98 – 1.03) 0.98 (0.92 – 1.03)
 Quartile 3 1.16 (1.14 – 1.19) 1.01 (0.99-1.03) 1.01 (0.99 – 1.03) 1.01 (0.96 – 1.08)
 Quartile 4 1.46 (1.43 – 1.49) 1.05 (1.03 – 1.07) 1.04 (1.02 – 1.06) 1.05 (0.99 – 1.11)
Ptrend <0.0001 <0.0001 0.0002 0.07
*Adjusted for age, gender, education level, SES and CCI category.
†Adjusted for age, gender, education level, SES, CCI category, serum glucose and triglycerides.
§Adjusted for age, gender, education level, SES, CCI category and BMI in the subgroup with BMI.
Table 3: Gender stratified hazard ratios (HR) and 95% Confidence Intervals (95%CI) for the risk of cancer by log and 
sex-specific quartiles of serum uric acid
No. of cancer/ Total 
participants
Men
HR (95%CI)
No. of cancer/ Total 
participants
Women
HR (95%CI)
Total group 41207/264799 31142/228482
Log serum uric acid 1.18 (1.12 – 1.24) 1.23 (1.17-1.29)
Serum uric acid
 Quartile 1 9471/64570 1.00 (Ref) 6299/56280 1.00 (Ref)
 Quartile 2 9945/67089 1.00 (0.97 – 1.03) 7169/57206 1.03 (1.00 – 1.07)
 Quartile 3 10596/66812 1.05 (1.02 – 1.07) 7932/57629 1.03 (0.99 – 1.06)
 Quartile 4 11195/66328 1.08 (1.05 – 1.11) 9742/57367 1.12 (1.09 – 1.16)
Ptrend <0.0001 <0.0001
Pinteraction <0.0001
All models were adjusted for age, education level, SES and CCI category.
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Table 4: Hazard ratios (HR) and 95% Confidence Intervals (95%CI) for the risk of different types of cancer by log and 
categories of serum uric acid in men
Site-specific 
cancer
Log Serum Uric 
Acid
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend
Prostate
 Events – n 3673 3860 4058 3988
 HR (95%CI) 0.92 (0.85 – 1.00) 1.00 (Ref) 0.97 (0.93 – 1.02) 1.00 (0.96 – 1.05) 1.02 (0.97 – 1.06) 0.08
Pulmonary
 Events – n 745 714 746 756
 HR (95%CI) 0.79 (0.66 – 0.95) 1.00 (Ref) 0.89 (0.80 – 0.99) 0.91 (0.82 – 1.00) 0.93 (0.84 – 1.03) 0.03
Colorectal
 Events – n 897 1012 1162 1269
 HR (95%CI) 1.55 (1.33 – 1.81) 1.00 (Ref) 1.05 (0.96 – 1.15) 1.17 (1.07 – 1.28) 1.31 (1.20 – 1.42) <0.0001
Gastroesophageal
 Events – n 290 319 336 341
 HR (95%CI) 1.04 (0.79 – 1.38) 1.00 (Ref) 1.02 (0.87 – 1.20) 1.05 (0.90 – 1.23) 1.08 (0.92 – 1.27) 0.83
Hepatobillary
 Events – n 143 142 159 241
 HR (95%CI) 2.03 (1.38 – 2.99) 1.00 (Ref) 0.92 (0.73 – 1.16) 1.00 (0.80 – 1.26) 1.56 (1.27 – 1.92) 0.0001
Pancreas
 Events – n 188 219 210 258
 HR (95%CI) 1.38 (0.98 – 1.94) 1.00 (Ref) 1.08 (0.89 – 1.32) 1.01 (0.83 – 1.23) 1.26 (1.05 – 1.52) 0.19
Kidney
 Events – n 220 247 276 303
 HR (95%CI) 1.52 (1.11 – 2.08) 1.00 (Ref) 1.05 (0.87 – 1.25) 1.13 (0.95 – 1.35) 1.27 (1.06 – 1.51) 0.02
Bladder
 Events – n 569 593 647 718
 HR (95%CI) 1.30 (1.06 – 1.59) 1.00 (Ref) 0.97 (0.86 – 1.08) 1.03 (0.92 – 1.15) 1.16 (1.04 – 1.30) 0.10
Head and neck
 Events – n 223 200 214 280
 HR (95%CI) 1.48 (1.06 – 2.08) 1.00 (Ref) 0.83 (0.69 – 1.01) 0.87 (0.72 – 1.05) 1.16 (0.97 – 1.38) 0.08
Melanoma
 Events – n 428 479 505 503
 HR (95%CI) 1.17 (0.93 – 1.48) 1.00 (Ref) 1.04 (0.91 – 1.18) 1.07 (0.94 – 1.21) 1.09 (0.95 – 1.23) 0.19
Non-melanoma 
Skin
 Events – n 416 476 521 630
 HR (95%CI) 1.59 (1.27 – 1.99) 1.00 (Ref) 1.06 (0.93 – 1.21) 1.14 (1.00 – 1.29) 1.42 (1.25 – 1.60) 0.0007
Central nervous 
system
 Events – n 260 242 257 213
 HR (95%CI) 0.60 (0.43 – 0.83) 1.00 (Ref) 0.87 (0.73 – 1.03) 0.89 (0.75 – 1.06) 0.74 (0.62 – 0.89) 0.005
(Continued )
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Site-specific 
cancer
Log Serum Uric 
Acid
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend
Lymphatic and 
Haematological
 Events – n 658 709 737 782
 HR (95%CI) 1.03 (0.86 – 1.25) 1.00 (Ref) 1.00 (0.90 – 1.11) 1.01 (0.91 – 1.12) 1.09 (0.99 – 1.21) 0.34
Other Cancer
 Events – n 761 733 768 913
 HR (95%CI) 1.23 (1.03 – 1.47) 1.00 (Ref) 0.92 (0.83 – 1.02) 0.99 (0.90 – 1.10) 1.28 (1.16 – 1.41) 0.009
All models were adjusted for age, education level, SES and CCI category.
Table 5: Hazard ratios (HR) and 95% Confidence Intervals (95%CI) for the risk of different types of cancer by log 
and categories of serum uric acid in women
Site-specific 
cancer
Log Serum Uric 
Acid
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend
Breast
 Events – n 2295 2570 2747 2782
 HR (95%CI) 0.94 (0.86 – 1.02) 1.00 (Ref) 1.00 (0.94 – 1.05) 0.99 (0.94 – 1.05) 0.93 (0.88 – 0.98) 0.03
Pulmonary
 Events – n 444 483 519 698
 HR (95%CI) 0.90 (0.74 – 1.08) 1.00 (Ref) 0.97 (0.85 - 1.10) 0.97 (0.85 – 1.10) 1.22 (1.08 – 1.37) 0.35
Colorectal
 Events – n 555 725 784 1077
 HR (95%CI) 0.92 (0.79 – 1.08) 1.00 (Ref) 1.16 (1.04 – 1.30) 1.17 (1.05 – 1.31) 1.50 (1.35 – 1.66) 0.16
Gastroesophageal
 Events – n 91 122 138 215
 HR (95%CI) 1.15 (0.80 – 1.65) 1.00 (Ref) 1.19 (0.91 – 1.56) 1.25 (0.96 – 1.63) 1.79 (1.40 – 2.29) 0.40
Hepatobillary
 Events – n 82 112 118 209
 HR (95%CI) 1.55 (1.06 – 2.27) 1.00 (Ref) 1.23 (0.92 – 1.63) 1.20 (0.91 – 1.60) 1.96 (1.52 – 2.53) 0.17
Pancreas
 Events – n 119 136 171 283
 HR (95%CI) 1.51 (1.09 – 2.10) 1.00 (Ref) 1.02 (0.79 – 1.30) 1.19 (0.94 – 1.50) 1.82 (1.47 – 2.26) 0.08
Kidney
 Events – n 88 104 121 193
 HR (95%CI) 1.83 (1.24 – 2.71) 1.00 (Ref) 1.05 (0.79 – 1.40) 1.14 (0.87 – 1.50) 1.68 (1.31 – 2.16) 0.08
Bladder
 Events – n 118 149 176 265
 HR (95%CI) 1.09 (0.79 – 1.52) 1.00 (Ref) 1.13 (0.88 – 1.43) 1.24 (0.98 – 1.57) 1.74 (1.40 – 2.16) 0.42
(Continued )
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Our results show some consistency with other 
similar studies. A meta-analysis of five prospective 
cohort studies [25–28] found that hyperuricemia was 
associated with an increased incidence of overall cancer 
(relative risk (RR): 1.03 (95%CI: 1.01 – 1.05, P=0.007)) 
[2]. Stratification by gender in the meta-analysis showed 
that hyperuricemia was significantly associated to risk 
of cancer in men, but not in women (RR: 1.05 (95%CI: 
1.02 – 1.08) and 1.01 (95%CI: 0.98 – 1.04), for men and 
women, respectively), however only one study specifically 
studied women. Furthermore, the meta-analysis suggested 
substantial heterogeneity between the studies (I2: 44.7 for 
cancer risk in men and women, 53.8 for cancer risk in 
men) [2]. Stratification by cancer site found a significant 
positive association between hyperuricemia and lymphatic 
and haematological cancers only [2]. This is inconsistent 
with our finding that hyperuricemia may be protective for 
lymphatic and haematological cancers in women, possibly 
due to differences in sample populations and sample 
sizes. The heterogeneity within our results, and between 
the previously described studies, may also be caused by 
confounders, in addition to plausible biological processes.
Serum uric acid concentration reflects the balance 
between uric acid synthesis and excretion. Increased 
production of serum uric acid may follow consumption of 
diets high in purines, acute alcohol consumption, chronic 
fructose consumption, and severe exercise [20]. Impaired 
function of the kidney, which primarily excretes uric acid, 
may also cause hyperuricemia [29]. Lifestyle factors and 
other chronic diseases potentially have an effect on the 
association between serum uric acid and cancer, for example, 
MetS is associated with the aforementioned dietary factors 
that cause increased production of serum uric acid [11, 20]. 
Reverse causation between uric acid and MetS has also been 
Site-specific 
cancer
Log Serum Uric 
Acid
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend
Gynaecological
 Events – n 833 890 1016 1337
 HR (95%CI) 1.22 (1.06 – 1.40) 1.00 (Ref) 0.95 (0.86 – 1.04) 1.01 (0.92 – 1.11) 1.23 (1.12 – 1.34) 0.12
Head and neck
 Events – n 75 86 105 160
 HR (95%CI) 1.90 (1.24 – 2.92) 1.00 (Ref) 1.02 (0.75 – 1.39) 1.16 (0.87 – 1.57) 1.65 (1.25 – 2.17) 0.004
Melanoma
 Events – n 314 320 371 337
 HR (95%CI) 0.90 (0.71 – 1.15) 1.00 (Ref) 0.91 (0.78 – 1.06) 0.98 (0.85 – 1.14) 0.83 (0.71 – 0.96) 0.63
Non-melanoma 
Skin
 Events – n 216 281 324 456
 HR (95%CI) 1.04 (0.81 – 1.33) 1.00 (Ref) 1.16 (0.97 – 1.39) 1.25 (1.05 – 1.49) 1.67 (1.42 – 1.96) 0.20
Central nervous 
system
 Events – n 228 238 224 213
 HR (95%CI) 0.67 (0.50 – 0.89) 1.00 (Ref) 0.93 (0.77 – 1.11) 0.81 (0.67 – 0.97) 0.71 (0.59 – 0.85) 0.003
Lymphatic and 
Haematological
 Events – n 404 414 445 595
 HR (95%CI) 0.80 (0.65 – 0.98) 1.00 (Ref) 0.91 (0.79 – 1.05) 0.91 (0.80 – 1.05) 1.13 (1.00 – 1.28) 0.01
Other Cancer
 Events – n 438 539 673 922
 HR (95%CI) 1.78 (1.50 – 2.11) 1.00 (Ref) 1.20 (1.06 – 1.37) 1.52 (1.35 – 1.72) 2.32 (2.07 – 2.59) <0.0001
All models were adjusted for age, education level, SES and CCI category.
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indicated given the fact that uric acid causes mitochondrial 
oxidative stress, stimulating accumulation of fat that is 
independent of excessive caloric intake [11, 30]. As MetS 
has been suggested as a risk factor for some cancers [26, 31], 
this complex association implies that serum uric acid levels 
may also be a result or a proxy for underlying MetS and/
or lifestyle risk factors for cancer. Nevertheless, we obtained 
similar results when we adjusted our analysis for MetS 
components, serum glucose and triglycerides.
To our knowledge, this is the largest study 
investigating serum uric acid and cancer risk in both 
men and women. We were able to account for MetS 
components by adjustments for serum glucose and lipids. 
The current study was strengthened by the large number 
of individuals with prospective measurements of serum 
uric acid available in the AMORIS database, all measured 
at one and the same laboratory. Complete follow up 
information, detailed information on cancer diagnosis, 
time of death and emigration was available for each 
participant through the use of national registers. Exposure 
and outcome information was obtained independently 
and assessed in an accurate manner [32]. The AMORIS 
population was selected following analysis of blood 
samples from health check-ups in non-hospitalised persons 
and is representative of the general working population of 
the greater Stockholm area in terms of SES and ethnicity. 
Over the course of the study, all-cause mortality was about 
14% lower in the AMORIS participants than in the general 
population of the greater Stockholm area, accounting for 
age, gender and calendar year [32]. The internal validity 
of our study is unaffected by the selection of a healthy 
cohort. There were no repeated measurements for serum 
uric acid available and no information on tumour severity. 
We did not have data on other lifestyle factors such as 
alcohol consumption, smoking status and diet for all 
study participants. Nevertheless, adjustment for CCI 
was considered as a proxy for other lifestyle-related 
disorders and did not alter the results. However, residual 
confounding may still have occurred which may have 
resulted in underestimation of the associations observed. 
Genetic information was unavailable for our study 
population, and it would be interesting to expand future 
analysis by combining genetic markers for serum uric acid. 
Finally, we observed higher risk of mortality with higher 
uric acid levels. Although we have adjusted our analysis 
for other co-morbidities, lower risks of some cancers with 
increasing serum uric acid need to be interpreted carefully 
due to the remaining possibility of competing risk, which 
is beyond the scope of this study. Future studies needs to 
address the above limitations to clarify any causal link 
between circulating uric acid and specific cancers.
In summary, increased levels of serum uric acid 
level were associated with risk of overall cancer in this 
large prospective cohort. The different directions of 
observed associations may corroborate the paradoxical 
role of uric acid as both an antioxidant and a prooxidant. 
Nevertheless, further investigations are needed to assess 
biological mechanisms that may clarify the link between 
uric acid metabolism and cancer.
MATERIALS AND METHODS
Study population and data collection
Blood samples of men and women from the greater 
Stockholm area were collected by the Central Automation 
Laboratory (CALAB) between 1985 and 1996. No other 
clinical data were included in the CALAB database for all 
participants [33]. The sample population was representative 
of the general working population of Stockholm. All 
participants were either healthy individuals undergoing 
clinical laboratory testing as part of a general health check-
up or outpatients referred for laboratory testing. None of the 
participants were inpatients at the time their blood samples 
were taken. The linkage of Swedish national registries, 
using the Swedish 10-digit personal identity number, to 
the CALAB database formed the AMORIS study and 
has been described in detail elsewhere [33–39]. Linkage 
to registries such as the National Cancer Register and 
the Hospital Discharge Register provided information on 
socio-economic status (SES), education level, vital status, 
cancer diagnosis and emigration. After a recent update, the 
AMORIS study now includes follow up information until 
31st December 2011 for 812,073 individuals [40].
We included 493,281 men and women aged 20 and 
older with baseline measurements of uric acid without 
any previous diagnosis of cancer. We excluded those 
with follow up less than 3 months to reduce reverse 
causation (i.e. serum uric acid levels can be affected by 
an undiagnosed cancer). An additional sensitivity analysis, 
in which the first 2 years of follow up were excluded, was 
also carried out to address the issue of reverse causation (n 
= 485,820). Follow up time was defined as the time from 
baseline measurement until date of cancer diagnosis, death 
from any cause, emigration or end of study (31st December 
2011), whichever occurred first. This study complied with 
the Declaration of Helsinki and was approved by the 
Ethics Review Board of the Karolinska Institute.
Definition of outcomes
The outcomes of this study were overall incident 
cancer and site-specific cancers. Diagnosis of cancer was 
obtained from the Swedish National Cancer Register. 
International Classification of Diseases, 7th revision 
(ICD-7) codes were used to classify major cancer sites 
(Supplementary Table 1, Supplementary Information).
Assessment of exposure and covariates
Uric acid was measured by enzymatic uricase method. 
Coefficients of variation for uric acid determinations 
Oncotarget9www.impactjournals.com/oncotarget
were <2.8% at 164 μmol/L (2.76 mg/dL), 2.3% at 470 
μmol/L (7.90 mg/dL) and 1.8% at 624 μmol/L (10.49 mg/
dL). Due to gender difference in serum uric acid levels 
[2, 20, 41, 42], we used sex-specific quartiles to classify 
levels of uric acid into four quartiles. Uric acid levels in 
men were grouped into quartile 1 (<281 μmol/L), quartile 
2 (281-319 μmol/L), quartile 3 (319-362 μmol/L) and 
quartile 4 (≥362 μmol/L). Uric acid levels in women were 
grouped into quartile 1 (<207 μmol/L), quartile 2 (207-240 
μmol/L), quartile 3 (240-279 μmol/L), and quartile 4 (≥279 
μmol/L). We additionally assess uric acid as a continuous 
variable by converting it logarithmically to ensure the 
normal distribution of the variable. Glucose was measured 
enzymatically with a glucoseoxidase/peroxidase method 
and Triglycerides (TG) were measured enzymatically with a 
glycerol-phosphate-oxidase after hydrolysis with lipoprotein 
lipase. Glucose (mmol/L) and triglycerides (TG; mmol/L) 
were assayed in 489,613 and 493,281 persons, respectively. 
Weight and height measurements were assessed in 66,931 
participants and body mass index (BMI) was calculated. All 
methods were fully automated with automatic calibration 
and performed at one accredited laboratory [35].
SES (white collar, blue collar, unemployed or 
unknown) was based on the national censuses [43]. 
Education level was categorised into low (less than high 
school), medium (high school equivalent), and high 
(higher education). Charlson comorbidity index (CCI) 
was calculated to account for other diseases given the 
association between serum uric acid and metabolic 
diseases. CCI was based on information from the National 
Patient Register and consisted of 17 groups of diseases 
with a specific weight assigned to each disease category, 
which were summed to obtain an overall score between 0 
and 3+ corresponding to comorbidity level [43].
Statistical analysis
Cox proportional hazards regression was 
used to estimate hazard ratios (HRs) and their 95% 
confidence intervals (95% CI) of overall cancer 
incidence by sex-specific quartiles of uric acid as well 
as the log transformation of uric acid. The assumption of 
proportionality of hazard was satisfied upon plotting levels 
of uric acid on Kaplan-Meier curves. In the multivariate 
model, we adjusted our analysis for age, gender, education 
level, SES, and CCI category. To assess whether this 
association was robust against adverse metabolic states, 
we performed further analyses adjusting for metabolic 
markers, i.e. serum glucose and triglycerides, and also 
adjusting for BMI as a continuous variable in the subgroup 
with information on BMI available.
We further stratified our analyses by gender to assess 
the incidence of overall cancer and each major cancer site 
and assessed the remaining cancers as one group (other 
cancers). We performed a Bonferroni correction, by 
dividing the significance threshold, 0.05, by the number 
of cancer sites assessed, fourteen in men and fifteen in 
women, to account for multiple testing in our cancer site-
specific analyses. We also performed a test for interaction 
by including the product of uric acid levels and gender 
in the models. To observe association between serum 
uric acid and mortality, a similar model assessing the 
association between uric acid levels and risk of overall 
death was carried out. All analyses were conducted with 
Statistical Analysis Systems (SAS) release 9.4 (SAS 
Institute, Cary, NC).
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